Scopus BioPharma
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
420 Lexington Ave Rm 300, New York, New ...Phone Number
(212) 479-2513Website
www.scopusbiopharma.comRevenue
$9.3 MillionStock Symbol
SCPSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Scopus BioPharma
Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The Company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate is highly distinctive, encompassing both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment. Additional STAT3-targeting immunotherapy drug candidates include bi-functional antisense and DNA-binding inhibition therapies. The Company is also seeking to develop additional drug candidates and to identify additional compelling technologies for potential acquisition, in-licensing and/or other similar transactions. Receive updates by following Scopus BioPharma on TwitteRead more
Popular SearchesScopus BioPharmaScopus Biopharma IncScopus CorpScopusbiopharmaSIC Code 28,283NAICS Code 32,325Ticker OTC: SCPSShow moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Scopus BioPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Scopus BioPharma had a recent Job posting/layoffs
Check out if Scopus BioPharma is spiking on competitors!
Scopus BioPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Scopus BioPharma has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Scopus BioPharma recently announced quarterly report
Check if Scopus BioPharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Scopus BioPharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Scopus BioPharma
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Scopus BioPharma
Compare insights from companies similar to Scopus BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Scopus BioPharma
$9.3M
11-50
Public
<$5M
2021
N/A
Company Profile Activity
Activity Insights
Scopus BioPharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Scopus BioPharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Scopus BioPharma.
Scopus BioPharma financials insights
Gather financial insights about Scopus BioPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$3M
Scopus BioPharma Tech Stack
A closer look at the technologies used by Scopus BioPharma
See more technologies
Most Recent Scoops
Funding
Initial Public Offering (IPO)
IPO, Funding
Initial Public Offering (IPO)
IPO
Initial Public Offering (IPO)
IPO
Initial Public Offering (IPO)
Scopus BioPharma News & Media
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma’s Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet Duet Being Positioned to Go Public in 2023 NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, aScopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharmaScopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-OncologyDR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC. BOARD OF DIRECTORS
NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (Nasdaq: SCPS) ("Scopus" or the "Company"), announced today...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Scopus BioPharma
Sign Up For FreeTo access detailed company insights
Scopus BioPharma Inc., both directly and through subsidiaries, is a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need. The Company's lead drug candidate is a novel, targeted immuno-oncology RNA therapy for the treatment of multiple cancers. This drug candidate... Read More
